Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Health Care Down As Investors Retreat From Growth Sectors -- Health Care Roundup

share with twitter share with LinkedIn share with facebook
09/04/2020 | 05:01pm EDT

Health-care companies fell as investors retreated from growth sectors, rotating into sectors that had not participated in the summer rally, such as financial and industrial companies.

A small Russian study of a Covid-19 vaccine showed promise with immune reactions, according to a paper published in prestigious British medical publication The Lancet.

Shares of Covid vaccine developer Moderna fell sharply after its chief executive said it was slowing down enrollment in the late-stage clinical trial vaccine to ensure diversity of the study's participants.

 

Write to Rob Curran at rob.curran@dowjones.com


share with twitter share with LinkedIn share with facebook
All news about MODERNA, INC.
10/23Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
DJ
10/23Canada to invest up to C$214 mln for research into domestic-made vaccines - P..
RE
10/23MODERNA : Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine against COV..
AQ
10/23MODERNA : Positive pre-clinical data for CureVac's COVID-19 vaccine
RE
10/22MODERNA : hits enrollment milestone for COVID-19 vaccine trial
AQ
10/22Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a..
RE
10/22MODERNA : US regulators seek advice on thorny issues as vaccines near
AQ
10/22MODERNA : Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COV..
BU
10/22Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
DJ
10/22MODERNA : US regulators seek advice on thorny issues as vaccines near
AQ
More news
Financials (USD)
Sales 2020 305 M - -
Net income 2020 -537 M - -
Net cash 2020 2 553 M - -
P/E ratio 2020 -49,5x
Yield 2020 -
Capitalization 27 830 M 27 830 M -
EV / Sales 2020 82,9x
EV / Sales 2021 4,96x
Nbr of Employees 975
Free-Float 89,8%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 91,47 $
Last Close Price 70,53 $
Spread / Highest target 92,8%
Spread / Average Target 29,7%
Spread / Lowest Target -41,9%
EPS Revisions
Managers
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.260.58%27 830
LONZA GROUP AG62.80%47 152
SEAGEN INC.72.54%34 263
IQVIA HOLDINGS INC.8.39%32 108
CELLTRION, INC.31.49%28 160
IMMUNOMEDICS, INC.315.22%20 324